title: Dobutamine prevents both myocardial stunning and phosphocreatine overshoot without affecting ATP level.
abstract: Catecholamines can overcome myocardial stunning. However, a previous report on energy metabolism in stunned myocardium during catecholamine infusion was based on the conventional biochemical methods which might affect contractile function. Twenty farm pigs were anesthetized and underwent 15 min coronary artery occlusion and 2 h reperfusion. Ten pigs were given 10 micrograms/kg/min dobutamine from immediately after and throughout the reperfusion (dobutamine group). The other ten pigs were given saline (control group). Phosphorus-31 magnetic resonance spectroscopy and sonomicrometry were done alternately. Dobutamine improved percent segment shortening after reperfusion (control/dobutamine = 3.8%-5.7%/11.7%-13.4%; P < 0.01). At 15 min ischemia, adenosine triphosphate (ATP) decreased (control/dobutamine = 72 +/- 8%/73 +/- 10%, n.s.), and remained depressed after reperfusion in both groups. After reperfusion, phosphocreatine (PCr) returned to and maintained the preischemic value in the dobutamine group, while in the control group, PCr overshoot (112 +/- 5%) was observed. Except for the presence and absence of PCr overshoot, there was no significant difference of ATP and PCr between the two groups, although rate pressure product was significantly higher in the dobutamine group than in the control group. Regional myocardial blood flow after reperfusion was significantly higher in the dobutamine group. Dobutamine may improve "stunning" through effective improvement of energy utilization and production, indicated by the disappearance of PCr overshoot and maintained ATP level.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kida
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
authors.forename: T
authors.initials: T
authors.lastname: Uegaito
authors.forename: M
authors.initials: M
authors.lastname: Miyamae
authors.forename: M
authors.initials: M
authors.lastname: Ohura
authors.forename: I
authors.initials: I
authors.lastname: Miura
authors.forename: Y
authors.initials: Y
authors.lastname: Yabuuchi
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002395:Catecholamines / Q000494:pharmacology; D004280:Dobutamine / Q000494:pharmacology*; D004734:Energy Metabolism / Q000502:physiology; D006321:Heart / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D009682:Magnetic Resonance Spectroscopy; D008854:Microscopy, Electron; D017682:Myocardial Stunning / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000737:chemistry / Q000473:pathology / Q000648:ultrastructure; D010725:Phosphocreatine / Q000378:metabolism*; D010761:Phosphorus Radioisotopes; D012039:Regional Blood Flow / Q000502:physiology; D015427:Reperfusion Injury / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology; D013552:Swine / Q000378:metabolism* / Q000502:physiology
chemical_list: D002395:Catecholamines; D010761:Phosphorus Radioisotopes; D010725:Phosphocreatine; D004280:Dobutamine; D000255:Adenosine Triphosphate